CLBS earnings
Caladrius Biosciences Inc. (CLBS) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business UpdateMerger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "The second quarter of 2022 was a transformative and energizing quarter for Caladrius with the announcement of our
- Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern TimeBASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three and six months ended June 30, 2022, on Thursday, August 4, 2022, at 4:30 p.m. (EDT). The Company is utilizing a new conference call service. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details for dial-in options. To avoid d
- Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular DysfunctionInterim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next development steps for XOWNA® to be announced by year-end 2022 following regulatory and business review Caladrius Management will host a conference call tomorrow, May 24th at 8:15 a.m. EDT BASKING RIDGE, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company has suspended patient enrollment in its Phase 2b study of XOWNA®, known as
- Caladrius Biosciences to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022, at 4:30 p.m. Eastern TimeBASKING RIDGE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three months ended March 31, 2022, on Thursday, May 5, 2022 at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below. Dial-in information: Conference ID: 7129748U.S. Toll-Free: 866-595-8403International: 706-758-9979 Please dial-in 10 minutes before the start of the conference call. A live webcast of th
- Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger AgreementCombined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong existing partnerships and potential for future attractive partnerships Lisata to combine development pipelines from both companies with an emphasis on advancing Cend's CendR Platform™ technology products in a range of solid tumor oncology indications The merged company projects a number of potential value-creating data and business development milestones over the next 24 months Caladrius to make an immediate investment of $10 million in Cend in connection with a development collaboration agreement
- Caladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateBASKING RIDGE, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, provides a business update and reports financial results for the three and twelve months ended December 31, 2021. "Caladrius made significant progress in 2021 that we believe has positioned us well to achieve several important milestones in 2022," stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius. "Highlights from 2021 include the initiation of our ongoing Phase 2b FREEDOM Trial of XOWNA® for the
- Caladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 22, 2022, at 4:30 p.m. Eastern TimeBASKING RIDGE, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three months and twelve months ended December 31, 2021, on Tuesday, March 22, 2022, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below. Dial-in information: Conference ID: 5066195U.S. Toll-Free: 866-595-8403International: 706-758-9979 Please dial-in 10 minutes before the start of the conference call
- Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial ResultsCompany Reports Strong Cash Position as it Prepares to Initiate a CD34+ Cell Therapy Study in Diabetic Kidney Disease Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, provides a corporate update and reports financial results for the three and nine months ended September 30, 2021. "Caladrius continued to advance and optimize its development programs in the third quarter despite the ongoing challenges to clinical devel
- Caladrius Biosciences to Host Third Quarter 2021 Financial Results Conference Call on Thursday, November 4th at 4:30 p.m. Eastern TimeBASKING RIDGE, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended September 30, 2021, on Thursday, November 4, 2021, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below. Dial-in information: Conference ID: 8378269U.S. Toll-Free: 866-595-8403International: 706-758-9979 A live webcast of the call will be available on the Caladrius website under the Investors &
- Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business UpdateBASKING RIDGE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results for the three and six months ended June 30, 2021. "The second quarter and first six months of 2021 have proven to be operationally and financially positive for Caladrius. Despite the continuing challenges presented by the COVID-19 pandemic, we continued to advance and expand our clinical pipeline while also adding a large amount of additional capital to our balance sheet," stated Davi
- Caladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business UpdateBASKING RIDGE, N.J. , May 06, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results for the three months ended March 31, 2021. "We are at a truly exciting point in our evolution with tremendous opportunities ahead of us. While the pandemic has impacted many companies, during the first quarter of 2021 we were able to both markedly strengthen our financial position and advance and expand our clinical pipeline," stated David J. Mazzo, Ph.D., President and Chief Executiv
- Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateCompany demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing Conference call begins today at 4:30 p.m. (ET) BASKING RIDGE, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results for the three and twelve months ended December 31, 2020. “Despite the continued headwinds of the global pandemic, we are pleased to report continued progress of our development programs as well as an improved fin